Key facts
- This page summarizes Michael Martin Breen's Form 4 filing for GT Biopharma, Inc. (GTBP).
- 3 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 08 Sep 2025, 17:45.
Michael Martin Breen - 04 Sep 2025 Form 4 Insider Report for GT Biopharma, Inc. (GTBP)
- Reporting relationship
- CEO and Director, Director
- Issuer ticker
- GTBP
- Reported as of
- 04 Sep 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Sep 2025, 17:45:43 UTC
- Prior SEC filing
- 15 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Martin Breen
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Michael Martin Breen filed Form 4 for GT Biopharma, Inc. (GTBP) on 08 Sep 2025.
Change
- Previous filing in this sequence was filed on 15 Aug 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001863633
Primary reporting owner
Breen Michael Martin
- Relationship
- CEO and Director, Director
- Address
- C/O GT BIOPHARMA, INC., 505 MONTGOMERY STREET, 10TH FLOOR, SAN FRANCISCO
- Signature
- /s/ Michael Martin Breen
- Signature date
- 08 Sep 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GTBP
transaction
Derivative
Option to purchase Common Stock
Award
- Transaction value
- $0
- Shares
- +100,000
- Change %
- Price
- $0.000000
- Shares after
- 100,000
- Date
- 04 Sep 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $1.33
- Footnotes
- F1
GTBP
transaction
Derivative
Option to purchase Common Stock
Award
- Transaction value
- $0
- Shares
- +100,000
- Change %
- Price
- $0.000000
- Shares after
- 100,000
- Date
- 04 Sep 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $1.33
- Footnotes
- F2
GTBP
transaction
Derivative
Option to purchase Common Stock
Award
- Transaction value
- $0
- Shares
- +100,000
- Change %
- Price
- $0.000000
- Shares after
- 100,000
- Date
- 04 Sep 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $1.33
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The options are fully vested and exercisable.
Footnote F2
The option vests in four equal quarterly installments beginning on January 1, 2025.
Footnote F3
The option vests in four equal quarterly installments beginning on January 1, 2026.